Chatham Lodging Trust (CLDT) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
23 Nov, 2025Executive summary
Completed sale of five hotels for $83 million at a 6% cap rate on 2024 NOI, targeting lower-performing assets and further de-leveraging the balance sheet.
Portfolio consisted of 34 hotels with 5,166 rooms across 15 states and D.C. as of June 30, 2025.
Initiated a $25 million share repurchase program, buying back 20,480 shares at a $7.02 average price in Q2.
Operationally, Q2 RevPAR and FFO per share were at the top of guidance, with occupancy at 82%, matching post-pandemic highs.
Net income to common shareholders was $3.4 million, down from $4.9 million year-over-year; diluted EPS was $0.07 vs. $0.10.
Financial highlights
Q2 2025 hotel EBITDA: $30.9 million; adjusted EBITDA: $28.5 million, both down year-over-year due to asset sales.
Adjusted FFO for Q2 2025 was $18.5 million ($0.36 per share), compared to $19.9 million ($0.39 per share) last year.
Total revenue for Q2 2025 was $80.3 million, down 7.2% year-over-year.
GOP margin for Q2: 46.3%, up 30 bps year-over-year; Hotel EBITDA margin declined 40 bps to 39%.
Declared $0.09 per share common dividend and $0.41406 per preferred share.
Outlook and guidance
Q3 2025 guidance: RevPAR $153–$156, growth of -1.5% to +0.5%, adjusted EBITDA $24.7–$26.8 million, adjusted FFO $0.29–$0.33 per share.
Full-year 2025 guidance: RevPAR flat to +1%, adjusted EBITDA $89–$93 million, adjusted FFO per share $0.95–$1.03.
Guidance assumes no further asset sales, capital markets activity, or floating rate changes.
Company expects to invest $9.3 million in renovations and improvements for the remainder of 2025.
Industry RevPAR decreased 0.5% for Q2 2025, with limited visibility for the remainder of 2025.
Latest events from Chatham Lodging Trust
- Industry-leading margins and RevPAR, strong balance sheet, and upside from tech market recovery.CLDT
Investor presentation2 Mar 2026 - Industry-leading margins, reduced leverage, and a return to profitability set the stage for 2026.CLDT
Q4 202527 Feb 2026 - Q2 RevPAR up 4%, Phoenix hotel acquired, and balance sheet strengthened despite higher costs.CLDT
Q2 20242 Feb 2026 - Q3 RevPAR growth, asset sales, and tech market strength support debt reduction and outperformance.CLDT
Q3 202416 Jan 2026 - Q4 RevPAR up 4%, margins expand, and leverage falls as tech markets drive growth.CLDT
Q4 202423 Dec 2025 - Proxy covers trustee elections, auditor ratification, executive pay, and equity plan amendment.CLDT
Proxy Filing2 Dec 2025 - Shareholders will vote on directors, auditor ratification, compensation, and plan amendment.CLDT
Proxy Filing2 Dec 2025 - Board urges approval of Equity Incentive Plan amendment to sustain aligned, cost-effective pay.CLDT
Proxy Filing2 Dec 2025 - Outperforming peers in RevPAR and margins, with strong growth potential from business travel recovery.CLDT
Investor Presentation27 Nov 2025